Key result
Routine Lp(a) testing is essential for comprehensive cardiovascular risk assessment.
Answers are grounded in this paper and cite their sources.
Routine measurement of Lipoprotein(a) is essential for accurate cardiovascular risk assessment and will become increasingly important as targeted Lp(a)-lowering therapies become available.
Lipoprotein(a) [Lp(a)] is a well recognised contributor in the development of cardiovascular disease. Unlike other lipoproteins, Lp(a) levels are primarily genetically determined, and in most individuals remain largely stable throughout life. Elevated Lp(a) is common in the general population, and various international guidelines now recommend at least one lifetime measurement of Lp(a) and its inclusion into an individual's cardiovascular risk assessment. Despite this, Lp(a) is still rarely measured, even in patients with known cardiovascular risk factors. Critically, the therapeutic landscape for Lp(a)-lowering medications is rapidly evolving with multiple drugs showing considerable promise in late-stage clinical trials. The strength and consistency of the evidence now cement Lp(a) as an essential biomarker of cardiovascular health. Failure to incorporate measurement of Lp(a) into clinical practice will continue to underestimate an individual's risk of CVD. Now is the time for Lp(a) to move from a neglected biomarker to a widely known and measured essential component of cardiovascular risk assessment.
No takes yet. Share an insight, caveat, or question.
Irvine et al. (2026) conducted a review in Cardiovascular disease. Lipoprotein(a) was evaluated. Lipoprotein(a) is an essential, genetically determined biomarker of cardiovascular health that should be incorporated into routine cardiovascular risk assessment.
Synapse has enriched 10 related papers. Consider them for comparative context: